Global Ovarian Cancer Diagnostics Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 11,647.12 |
 CAGR |
% |
| Principais participantes do mercado |
Mercado global de diagnóstico de cancro do ovário, por tipo de produto (instrumentos, kits e reagentes), tipo de procedimento (teste de biópsia, teste de imagem médica, teste de marcadores sanguíneos e testes genéticos ), tipo de cancro (células germinativas, tumor epitelial e tumor de células estromais), fim Utilizador (Centros de Diagnóstico de Cancro, Laboratórios Hospitalares, Institutos de Investigação e Outros) - Tendências e Previsões do Sector para 2030.
Análise e insights do mercado de diagnóstico do cancro do ovário
O cancro do ovário é o tipo de cancro que se forma nos tecidos do ovário (uma de um par de glândulas reprodutivas femininas nas quais os óvulos, ou óvulos, são formados). A maioria dos cancros do ovário são cancros epiteliais do ovário (cancro que começa nas células da superfície do ovário) ou tumores malignos das células germinativas (cancro que começa nos óvulos). Os exames e procedimentos utilizados para diagnosticar o cancro do ovário incluem o exame pélvico, exames de imagem, análises ao sangue, cirurgia e entre outros. Durante um exame pélvico, o médico insere os dedos enluvados na vagina e, simultaneamente, pressiona a mão no abdómen para sentir (palpar) os órgãos pélvicos.
O mercado global de diagnóstico do cancro do ovário deverá crescer no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,0% no período de previsão de 2023 a 2030 e deverá atingir os 11.647,12 milhões de dólares até 2030.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2020-2016) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Por tipo de produto (instrumentos, kits e reagentes), tipo de procedimento (teste de biópsia, teste de imagem médica, teste de marcadores sanguíneos e testes genéticos), tipo de cancro (células germinativas, tumor epitelial e tumor de células estromais), utilizador final (centros de diagnóstico de cancro, Laboratórios Hospitalares, Institutos de Investigação e Outros) |
|
Países abrangidos |
EUA, Canadá e México, Alemanha, França, Reino Unido, Itália, Espanha, Países Baixos, Rússia, Suíça, Turquia, Bélgica e resto da Europa, China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia , Filipinas e Resto da Ásia-Pacífico, Brasil, Argentina e Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
F. Hoffmann-La Roche Ltd, Tosoh Índia Unip. Ltd., Luminex Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Ngenebio, Abbott, Siemens Healthcare Private Limited, Myriad Genetics Inc., Bio-rad Laboratory, Inc., R&D Systems, Inc., Foundation Medicine, Inc., Biosupply ltd, Lcm genect srl, Inex innovate private limited, Abcam plc., Monobind Inc., Fujirebio, Mp biomedicals, Biovision Inc., Boster biological technology, Biogenix Inc. Ltd., Genway biotech e Lifespan biosciences, Inc. |
Definição de mercado do mercado global de diagnóstico de cancro do ovário
O cancro do ovário é mais comum em mulheres com idades compreendidas entre os 50 e os 79 anos. o desenvolvimento do mercado de diagnóstico do cancro do ovário. O aumento do investimento governamental na sensibilização para a detecção precoce do cancro, bem como o aumento das despesas com os cuidados de saúde, também impulsionariam o crescimento das empresas. A obesidade parece desempenhar um papel significativo no desenvolvimento do cancro do ovário. Outras opções de estilo de vida que podem aumentar o risco incluem fumar, beber e não ter filhos. Como o cancro do ovário não é facilmente detetável, as mulheres que correm o risco de desenvolver a doença devem ser submetidas a exames de rotina para identificar precocemente a doença, permitindo a expansão do mercado.
O mercado global de diagnóstico do cancro do ovário está a crescer no ano previsto devido ao aumento dos players do mercado e à disponibilidade de serviços avançados. Juntamente com isto, os fabricantes estão empenhados em atividades de I&D para lançar novos serviços no mercado. A crescente investigação em diagnóstico e desenvolvimento do cancro do ovário está a impulsionar ainda mais o crescimento do mercado. No entanto, as dificuldades nas técnicas de rastreio do cancro do ovário podem dificultar o crescimento do mercado global de diagnóstico do cancro do ovário no período de previsão.
Dinâmica global do mercado de diagnóstico do cancro do ovário
Motoristas
- Crescente consciencialização sobre o cancro do ovário
A crescente consciencialização sobre o cancro do ovário levou a um aumento da procura pela deteção atempada do cancro, levando ao crescimento do mercado.
O cancro do ovário é uma das principais causas do aumento das taxas de mortalidade entre as populações femininas de todo o mundo, o que alimenta o crescimento do mercado nos próximos cinco anos. O cancro nos ovários e nos quistos está a tornar-se mais comum devido a vários fatores, como fatores ambientais e mutações genéticas.
O cancro do ovário é um tipo de cancro que afeta os órgãos produtores de óvulos das mulheres, os ovários. O cancro do ovário é difícil de diagnosticar porque os sintomas são vagos e muitas vezes são detetados apenas depois de o cancro se espalhar pelo estômago e pela pélvis, dificultando a cura.
Como resultado, são necessários processos e técnicas de diagnóstico melhorados para determinar o estádio do cancro a tratar. Além disso, o aumento da taxa de mortalidade por cancro do ovário é preocupante, enfatizando a importância da detecção precoce para que o tratamento possa ser fornecido.
Devido ao aumento da consciencialização sobre o cancro do ovário, espera-se que atue como um fator impulsionador para o crescimento do mercado.
- Processos e técnicas de diagnóstico melhorados
Os testes e exames de rastreio são utilizados para detetar uma doença, como o cancro, em pessoas que não apresentam sintomas. Tem havido muita investigação para desenvolver um teste de rastreio para o cancro do ovário, mas não houve muito sucesso até agora. Os dois exames utilizados com maior frequência (além de um exame pélvico completo) para despiste do cancro do ovário são a ecografia transvaginal (USTV) e o exame de sangue CA-125.
O TVUS é um exame que utiliza ondas sonoras para observar o útero, as trompas de Falópio e os ovários, colocando uma varinha de ecografia na vagina. Pode ajudar a encontrar uma massa (tumor) no ovário, mas não pode realmente dizer se uma massa é cancerígena ou benigna. Quando é utilizado para rastreio, a maioria das massas encontradas não são cancro.
O exame de sangue CA-125 mede a quantidade de uma proteína chamada CA-125 no sangue. Muitas mulheres com cancro do ovário apresentam níveis elevados de CA-125. Este teste pode ser útil como marcador tumoral para ajudar a orientar o tratamento em mulheres com cancro do ovário conhecido, porque um nível elevado geralmente diminui se o tratamento estiver a funcionar. Mas a verificação dos níveis de CA-125 não é tão útil como um teste de rastreio do cancro do ovário.
Assim, devido ao aumento de processos e técnicas de diagnóstico melhorados, espera-se que atue como um fator impulsionador para o crescimento do mercado.
RESTRIÇÕES
Elevado custo de diagnóstico
Em todo o mundo, os custos do tratamento do cancro aumentaram. As indústrias da saúde enfrentam vários desafios, como os custos médicos para o tratamento do cancro. O custo dos cuidados oncológicos em 2010 foi de 124,60 mil milhões de dólares, prevendo-se que aumente para 173,00 mil milhões de dólares até 2020, sendo os preços dos medicamentos contra o cancro e os cuidados hospitalares agudos os principais impulsionadores. Assim, o aumento do custo de produção de agentes de diagnóstico está a dificultar o crescimento do mercado.
Falta de profissionais qualificados
Os profissionais de saúde envolvidos no processo de diagnóstico têm a obrigação e a responsabilidade ética de empregar competências de raciocínio clínico, avaliar e gerir os problemas médicos de um doente. Quando um diagnóstico é preciso e feito em tempo útil, o paciente tem a melhor oportunidade de obter um resultado de saúde positivo, porque a tomada de decisão clínica será adaptada para uma compreensão correta do problema de saúde do paciente. A falta de profissionais qualificados pode dificultar o processo de recuperação do paciente e, assim, dificultar o crescimento do mercado.
OPORTUNIDADES
Aumento dos gastos com a saúde para o diagnóstico e tratamento do cancro
Em todo o mundo, as actividades de I&D estão a aumentar devido às despesas de saúde pública com desempenhos económicos, ao passo que o sector dos cuidados de saúde ocupa o segundo lugar entre todos os sectores no que diz respeito ao montante gasto em cuidados de saúde . O aumento das despesas com cuidados de saúde pode resultar numa melhor oferta de oportunidades de I&D. Prevê-se que aumente a procura por diagnósticos de cancro do ovário.
O aumento dos gastos com os cuidados de saúde para o tratamento do cancro também ajuda os doentes a realizar diagnósticos e tratamentos avançados sem complicações para uma recuperação rápida. As despesas com cuidados de saúde são constituídas pela combinação de pagamentos directos (pessoas que pagam pelos seus próprios cuidados), despesas governamentais e fontes que incluem seguros de saúde e actividades de Organizações Não Governamentais (ONG). Devido a este aumento dos gastos com a saúde para o tratamento do cancro, funciona como uma oportunidade de crescimento do mercado.
DESAFIOS
Regulamentação e normas rigorosas para aprovação e comercialização de produtos para diagnóstico de cancro
The stringent regulations for commercialization of any product in the market are proving to be a big challenge for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has its own regulations and has a different body for regulatory procedures.
In the U.S., manufacturers require marketing authorization approval for IVD products for human use. The product must be labeled in accordance with labeling regulations. Establishments involved in the production and distribution of medical devices intended for commercial distribution in the U.S. are required to register with the FDA. Registration provides the FDA with the location of medical device manufacturing facilities and importers. Registration of an establishment is not an approval of the establishment or its devices by the FDA, that is, it does not provide FDA authorization to market the device. Unless exempted, premarketing authorization is required before a device can be placed into commercial distribution in the U.S.
The regulatory requirement for approvals of marketing as well as the declaration of conformity and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval on the products, manufacturers are not able to launch their product in the market and for this reason, strict regulations and standards for the approval and commercialization of cancer diagnostic products act as a restraining factor for market growth.
Recent Developments
- In November 2022, Myriad genetics Inc. announced that it has acquired Gateway Genomics, LLC, The acquisition strengthens Myriad Genetics’ portfolio of Women’s Health products, expanding access to personalized genetic tests during the reproductive stage of a women’s life and beyond. With SneakPeek, Myriad now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for all ancestries, this will help the company to increase their revenue.
- In October 2022, Quest Diagnostics announced the new phase of collaboration with Decode health, in the starting phase of collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets for different types of cancers (breast, prostate and ovarian cancer). This collaboration helps the company to find innovative paths in the field of R&D and increases the global presence of the company.
Global Ovarian Cancer Diagnostics Market Scope
Global ovarian cancer diagnostics market is segmented into product type, procedure type, cancer type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Kits and Reagents
On the basis of product type, the global ovarian cancer diagnostics market is segmented into instruments and kits and reagents.
Procedure Type
- Blood Markers Testing
- Medical Imaging Test
- Biopsy Tests
- Genetic Testing
On the basis of procedure type, the global ovarian Cancer Diagnostics market is segmented into blood markers testing, medical imaging test, biopsy tests and genetic testing
Cancer Type
- Epithelial Tumor
- Germ Cell
- Stromal Cell Tumor
On the basis of cancer type, the global ovarian cancer diagnostics market is segmented into epithelial tumor, germ cell and stromal cell tumor
End User
- Cancer Diagnostic Centers
- Hospital Laboratories
- Research Institutes
- Others
On the basis of end user, the global ovarian cancer diagnostics market is segmented into cancer diagnostic centers, hospital laboratories, research institutes and others
Global Ovarian Cancer Diagnostics Market Regional Analysis/Insights
The global ovarian cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, procedure type, cancer type and end user, as referenced above.
The countries covered in this market report are U.S., Canada and Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel and Rest of Middle East and Africa.
North America is dominating the global ovarian cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting the market
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Ovarian Cancer Diagnostics Market Share Analysis
O panorama competitivo do mercado de diagnóstico do cancro do ovário fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de diagnóstico do cancro do ovário.
Alguns dos principais players que operam no mercado global de diagnóstico do cancro do ovário são a F. Hoffmann-La Roche Ltd, a Tosoh India Pvt. Ltd., Luminex Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Ngenebio, Abbott, Siemens Healthcare Private Limited, Myriad Genetics Inc., Bio-rad Laboratory, Inc., R&D Systems, Inc., Foundation Medicine, Inc., Biosupply ltd, Lcm genect srl, Inex innovate private limited, Abcam plc., Monobind Inc., Fujirebio, Mp biomedicals, Biovision Inc., Boster biological technology, Biogenix Inc. Ltd., Genway biotech e Lifespan biosciences, Inc, entre outras.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS
5.1 CONCLUSION
6 REGULATIONS OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING OVARIAN CANCER AWARENESS
7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES
7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR
7.1.4 IMPROVED IMAGING TECHNIQUES
7.2 RESTRAINS
7.2.1 HIGH COST OF DIAGNOSIS
7.2.2 ADVERSE EFFECTS OF THE TREATMENT
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED PROFESSIONALS
8 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 KITS AND REAGENTS
9 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 BLOOD MARKERS TESTING
9.3 MEDICAL IMAGING TEST
9.4 BIOPSY TEST
9.5 GENETIC TESTING
10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 EPITHELIAL TUMOR
10.3 GERM CELL
10.4 STROMAL CELL TUMOR
11 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 CANCER DIAGNOSTIC CENTERS
11.3 HOSPITAL LABORATORIES
11.4 RESEARCH INSTITUTES
11.5 OTHERS
12 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U.S.
12.2.2 CANADA
12.2.3 MEXICO
12.3 EUROPE
12.3.1 GERMANY
12.3.2 FRANCE
12.3.3 U.K.
12.3.4 ITALY
12.3.5 SPAIN
12.3.6 RUSSIA
12.3.7 TURKEY
12.3.8 BELGIUM
12.3.9 NETHERLANDS
12.3.10 SWITZERLAND
12.3.11 REST OF EUROPE
12.4 ASIA-PACIFIC
12.4.1 JAPAN
12.4.2 CHINA
12.4.3 SOUTH KOREA
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 SINGAPORE
12.4.7 THAILAND
12.4.8 MALAYSIA
12.4.9 INDONESIA
12.4.10 PHILIPPINES
12.4.11 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 SAUDI ARABIA
12.6.3 U.A.E
12.6.4 EGYPT
12.6.5 ISRAEL
12.6.6 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F. HOFFMANN-LA ROCHE LTD
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 TOSOH INDIA PVT. LTD.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION (2022)
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 QUEST DIAGNOSTICS INCORPORATED (2022)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 THERMO FISHER SCIENTIFIC INC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABCAM PLC (2022)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 1.7.4 RECENT DEVELOPMENT
15.8 BIOSUPPLY LTD
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RADBIO LABORATORIES
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOVISION INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOGENIX INC. PVT. LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 BOSTER BIOLOGICAL TECHNOLOGY
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 FOUNDATION MEDICINE
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 FUJIREBIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GENWAY BIOTECH
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INEX INNOVATIVE PRIVATE LIMITED
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 LCM GENETIC SRL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 LIFESPAN BIOSCIENCES, INC
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 MP BIOMEDICALS
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 MONOBIND INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 MYRIAD GENETICS, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 NGENEBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENTS
15.23 R&D SYSTEMS, INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 SIEMENS MEDICAL SOLUTIONS
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION)
TABLE 2 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 26 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 27 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 28 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 29 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 30 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 31 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 32 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 33 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 34 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 35 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 36 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 38 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 40 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 44 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 48 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 49 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 50 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 52 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 53 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 54 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 56 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 60 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 61 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 64 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 65 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 68 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 72 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 73 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 74 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 76 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 77 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 78 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 80 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 81 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 84 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 85 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 86 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 87 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 89 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 91 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 93 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 94 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 97 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 98 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 99 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 105 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 106 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 107 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 109 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 112 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 113 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 114 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 117 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 118 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 119 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 121 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 122 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 123 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 125 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 127 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 129 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 130 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 131 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 133 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 134 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 135 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 136 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 138 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 139 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 142 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 143 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 144 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 146 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 147 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 REST OF SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 149 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 150 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 152 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 153 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 154 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 156 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 157 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 158 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 160 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 161 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 162 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 164 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 166 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 168 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 169 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 170 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 172 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 173 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 174 REST OF MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030
FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET , AND ASIA-PACIFI IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 EUROPE IS THE FASTEST-GROWING MARKET FOR GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET
FIGURE 16 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022
FIGURE 21 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION)
FIGURE 22 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030)
FIGURE 23 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 25 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 26 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 27 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 29 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 30 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 31 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 33 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY COUNTRY (2022)
FIGURE 34 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY COUNTRY (2023 & 2030)
FIGURE 35 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 36 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY PRODUCTS (2023-2030)
FIGURE 37 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 42 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 44 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 47 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 48 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 49 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 52 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 53 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 54 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 55 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 56 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 57 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 58 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 59 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 60 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 61 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 62 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 63 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 64 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 65 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
